(−)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells.

MLA

Ying, Le, et al. “(−)-Epigallocatechin-3-Gallate and EZH2 Inhibitor GSK343 Have Similar Inhibitory Effects and Mechanisms of Action on Colorectal Cancer Cells.” Clinical & Experimental Pharmacology & Physiology, vol. 45, no. 1, Jan. 2018, pp. 58–67. EBSCOhost, https://doi.org/10.1111/1440-1681.12854.

APA

Ying, L., Yan, F., Williams, B. R. G., Xu, P., Li, X., Zhao, Y., Hu, Y., Wang, Y., Xu, D., & Dai, J. (2018). (−)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells. Clinical & Experimental Pharmacology & Physiology, 45(1), 58–67. https://doi.org/10.1111/1440-1681.12854

Chicago

Ying, Le, Feng Yan, Bryan R. G. Williams, Ping Xu, Xin Li, Yueling Zhao, Yiqun Hu, Yuefei Wang, Dakang Xu, and Jing Dai. 2018. “(−)-Epigallocatechin-3-Gallate and EZH2 Inhibitor GSK343 Have Similar Inhibitory Effects and Mechanisms of Action on Colorectal Cancer Cells.” Clinical & Experimental Pharmacology & Physiology 45 (1): 58–67. doi:10.1111/1440-1681.12854.